Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study

OBJECTIVES: The efficacy and safety of sifalimumab were assessed in a phase IIb, randomised, double-blind, placebo-controlled study (NCT01283139) of adults with moderate to severe active systemic lupus erythematosus (SLE). METHODS: 431 patients were randomised and received monthly intravenous sifali...

Descripción completa

Detalles Bibliográficos
Autores principales: Khamashta, Munther, Merrill, Joan T, Werth, Victoria P, Furie, Richard, Kalunian, Kenneth, Illei, Gabor G, Drappa, Jorn, Wang, Liangwei, Greth, Warren
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2016
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5099191/
https://www.ncbi.nlm.nih.gov/pubmed/27009916
http://dx.doi.org/10.1136/annrheumdis-2015-208562

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5099191/
https://www.ncbi.nlm.nih.gov/pubmed/27009916
http://dx.doi.org/10.1136/annrheumdis-2015-208562

Ejemplares similares